Biogen is leaning on newer drugs, including recently acquired assets, as its multiple sclerosis franchise faces ongoing competition.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack. ·
Barrons.com
·
Courtesy of Biogen
